CPA
ABBV icon

Capital Performance Advisors’s AbbVie ABBV Stock Holding History

Capital Performance Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Sell
5,103
-1,231
-19% -$265K 0.08% 97
2026
Q1 		$1.38M Buy
6,334
+546
+9% +$121K 0.09% 98
2025
Q4 		$1.32M Buy
5,788
+2,047
+55% +$466K 0.09% 95
2025
Q3 		$866K Buy
3,741
+610
+19% +$124K 0.14% 80
2025
Q2 		$581K Buy
3,131
+145
+5% +$26.9K 0.11% 97
2025
Q1 		$626K Buy
2,986
+1,647
+123% +$320K 0.14% 75
2024
Q4 		$238K Buy
1,339
+36
+3% +$6.62K 0.08% 125
2024
Q3 		$257K Buy
1,303
+73
+6% +$13.6K 0.08% 90
2024
Q2 		$211K Buy
1,230
+44
+4% +$7.29K 0.08% 82
2024
Q1 		$216K Buy
+1,186
New +$204K 0.08% 77

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Performance Advisors's ABBV Position: Q2 2026 in Review

Capital Performance Advisors reduced its AbbVie (ABBV) stake by 19% in Q2 2026, selling an estimated $265K and leaving 5,103 shares worth $1.28M. The position accounts for 0.08% of the portfolio, ranked #97.

Capital Performance Advisors first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.38M in Q1 2026. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Capital Performance Advisors held 5,103 shares of AbbVie worth $1.28M as of Q2 2026.
  • Capital Performance Advisors sold 1,231 AbbVie shares in Q2 2026, an estimated $265K.
  • AbbVie made up 0.08% of Capital Performance Advisors's portfolio in Q2 2026, its #97 holding.
  • Capital Performance Advisors first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
  • Capital Performance Advisors's AbbVie position peaked at $1.38M in Q1 2026.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.